Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Up 5.81%
As of Monday, October 19, Celldex Therapeutics, Inc.’s CLDX share price has surged by 5.81%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Commentary & Analysis
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 5.31%
As of Thursday, October 08, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 5.31%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 5.95%
As of Wednesday, September 23, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 5.95%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 16.13%
As of Tuesday, September 22, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 16.13%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 11.07%
As of Tuesday, September 22, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 11.07%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,333.9 | $219.1 | 57% |
|
| Shares Out (Mil) | 77.8 | 53.4 | 57% |
|
| Institutional Ownership | 99.8% | 92.9% | 94% |
|
| Float (Mil) | 73.0 | 41.4 | 55% |
|
| Beta | 0.84 | 0.95 | 49% |
|
| Avg Daily Volume (000s) | 873 | 455 | 67% |
|
| Price Change (52-week) |
11.2% | 46.6% | 61% |
|
| Growth | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (27.3%) | 13.2% | 1% |
|
| Net Income (5yr) | (34.0%) | (10.1%) | 12% |
|
| EPS (5yr) | (14.1%) | 15.8% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (60.9%) | (15.7%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($1.011) | ($4.124) | ($4.251) | |
| Month Ago EPS | ($1.011) | ($4.124) | ($4.237) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.076) | ($4.352) | ($4.370) | |
| Year/Year Chg | 7.1% | 5.9% | (8.8%) | |
| Financials | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 0% |
|
| Net Income (TTM) (Mil) | ($301) | ($44) | 5% |
|
| EPS (TTM) | ($4.334) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($236) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $24 | $1 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $2,563 | $174 | 52% |
|
| Valuation | CLDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.27 | 2.11 | 71% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (70.6%) | na |
|
| ROA | (40.8%) | (47.0%) | 13% |
|
| ROE | (43.9%) | (52.2%) | 17% |
|
| Liabilities to Assets | 8.7% | 29.6% | 5% |
|
| F-Score | 1 | 2 | 1% |
|
Celldex Therapeutics, Inc. did not pass any screens on 11/3/2026.
